142 related articles for article (PubMed ID: 36510653)
1. A Nationwide Study of Differences in Surgical Treatment Rates and Oncological Outcomes for Prostate Cancer according to Economic Status and Region.
Yoo S; Oh S; Cho MC; Son H; Jeong H
Cancer Res Treat; 2023 Apr; 55(2):652-658. PubMed ID: 36510653
[TBL] [Abstract][Full Text] [Related]
2. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
Lee W; Lim B; Kyung YS; Kim CS
Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.
Ilic D; Evans SM; Allan CA; Jung JH; Murphy D; Frydenberg M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009625. PubMed ID: 28895658
[TBL] [Abstract][Full Text] [Related]
5. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.
Makino K; Nakagawa T; Ito E; Kasahara I; Murata T; Fujimura T; Fukuhara H; Homma Y
Jpn J Clin Oncol; 2018 May; 48(5):485-490. PubMed ID: 29635526
[TBL] [Abstract][Full Text] [Related]
6. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy.
Milonas D; Laenen A; Venclovas Z; Jarusevicius L; Devos G; Joniau S
Clin Transl Oncol; 2022 Feb; 24(2):371-378. PubMed ID: 34453699
[TBL] [Abstract][Full Text] [Related]
7. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
[TBL] [Abstract][Full Text] [Related]
8. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?
Taguchi S; Fukuhara H; Morikawa T; Matsumoto A; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1143-1147. PubMed ID: 27620729
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
Maru S; Uchino H; Osawa T; Chiba S; Mouri G; Sazawa A
PLoS One; 2018; 13(5):e0197252. PubMed ID: 29795595
[TBL] [Abstract][Full Text] [Related]
11. Early oncological and functional outcomes following radical treatment of high-risk prostate cancer in men older than 70 years: A prospective longitudinal study.
Paterson C; Alashkham A; Lang S; Nabi G
Urol Oncol; 2016 Aug; 34(8):335.e1-7. PubMed ID: 27083115
[TBL] [Abstract][Full Text] [Related]
12. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
[TBL] [Abstract][Full Text] [Related]
13. Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy.
Kunz I; Musch M; Roggenbuck U; Klevecka V; Kroepfl D
BJU Int; 2013 Mar; 111(3 Pt B):E24-9. PubMed ID: 22947135
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
15. Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study.
Ishizaki F; Hara N; Koike H; Kawaguchi M; Tadokoro A; Takizawa I; Nishiyama T; Takahashi K; Hohenfellner R
Diagn Pathol; 2012 Jun; 7():68. PubMed ID: 22697234
[TBL] [Abstract][Full Text] [Related]
16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
17. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.
Boehm K; Beyer B; Tennstedt P; Schiffmann J; Budaeus L; Haese A; Graefen M; Schlomm T; Heinzer H; Salomon G
World J Urol; 2015 Jun; 33(6):801-6. PubMed ID: 24989847
[TBL] [Abstract][Full Text] [Related]
18. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
19. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]